← Back to Search

Small Molecule Inhibitor

Sotorasib + Tarloxotinib for Non-Small Cell Lung Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Medical University of South Carolina

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from the date of first study drug dose to the date of death by any cause, up to approximately 100 months.

Awards & highlights

Study Summary

This trial is testing a new combination drug to treat KRAS G12C mutation NSCLC that has progressed despite other small molecule treatments.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from the date of first study drug dose to the date of death by any cause, up to approximately 100 months.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from the date of first study drug dose to the date of death by any cause, up to approximately 100 months.

This trial's timeline: 3 weeks for screening, Varies for treatment, and from the date of first study drug dose to the date of death by any cause, up to approximately 100 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response

Secondary outcome measures

Best overall response

Disease control rate

Duration of Response

+2 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: STAGE 2: EFFICACY (n=12)Experimental Treatment1 Intervention

EFFICACY (n=12)

Group II: STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored)Experimental Treatment1 Intervention

SAFETY LEAD IN (n=6-18, depending on number of DLs explored) 3+3 design dependent on DLTs

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Rain Therapeutics Inc.Industry Sponsor

4 Previous Clinical Trials

277 Total Patients Enrolled

Rain Oncology IncIndustry Sponsor

8 Previous Clinical Trials

314 Total Patients Enrolled

Medical University of South CarolinaLead Sponsor

933 Previous Clinical Trials

7,394,610 Total Patients Enrolled

Media Library

Sotorasib (Small Molecule Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05313009 — Phase 1 & 2

Non-Small Cell Lung Cancer Research Study Groups: STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored), STAGE 2: EFFICACY (n=12)

Non-Small Cell Lung Cancer Clinical Trial 2023: Sotorasib Highlights & Side Effects. Trial Name: NCT05313009 — Phase 1 & 2

Sotorasib (Small Molecule Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05313009 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size of participants in this research endeavor?

"Affirmative. The details posted on clinicaltrials.gov demonstrate that this research is currently accepting patients. It was first announced on March 7th 2022 and has since been updated November 3rd of the same year. 30 volunteers are expected to join at a single medical centre."

Answered by AI

Are there any remaining openings for participation in this clinical investigation?

"Affirmative. Information found on clinicaltrials.gov reveals that this research is currently enrolling participants. It was published on March 7th 2022 and recently modified in November of the same year; the study requires 30 patients from one location to complete it."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

2022. "Tarlox and Sotorasib in Patients With KRAS G12C Mutations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05313009.